Concepedia

Yuki Tomizawa

YT

4

Publications

1.4K

Citations

4

H-Index

2007

Active since

Affiliations

PTC Therapeutics (United States)(Current)

University of Massachusetts Chan Medical School

Yuki Tomizawa is an author at PTC Therapeutics (United States) specializing in genetics, medicine, and pharmacology.

Top concepts

Publications per year

2007–2018

4

Publications

4

PTC124 targets genetic disorders caused by nonsense mutations

Ellen Welch, Elisabeth R. Barton, Jin Zhuo et al. · Nature · 2007 · 1.1K citations

, , +4

Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression

Bijoyita Roy, Westley J. Friesen, Yuki Tomizawa et al. · Proceedings of the National Academy of Sciences · 2016 · 221 citations · Full text

The nucleoside analog clitocine is a potent and efficacious readthrough agent

Westley J. Friesen, Christopher R. Trotta, Yuki Tomizawa et al. · RNA · 2017 · 47 citations · Full text

, , +15

The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential

Westley J. Friesen, Briana Johnson, Jairo Sierra et al. · PLoS ONE · 2018 · 38 citations · Full text

Rows per page

1–4 of 4